+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

‘Gene Therapy Market Set To Grow At A Cagr Of 41.1% In The First Half Of The Forecast Period’ says Visiongain

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Gene Therapy R&D and Revenue Market Report : Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players

The gene therapy market is still establishing itself and many opportunities are available to explore at the moment. One opportunity in this market is for smaller biotechnology companies, which because of their size and infrastructure may be able to develop an orphan drug quicker than a Big Pharma company can. Another opportunity in the gene therapy market is the development of novel technologies such as CRISPR (clustered regularly interspaced short palindromic repeats). Gene therapy has seen many advances in recent years, such as improvement in viral vector delivery for safe and efficacious gene delivery and expression.

The lead analyst of the report commented “The growth of the overall gene therapy market will be driven by the immense pipeline of gene therapies in development. Many gene therapies in development target orphan diseases with high unmet need, this pipeline includes therapies that cover a wide range of indications for the cancer, cardiovascular, ophthalmologic, rare diseases, musculoskeletal, neurodegenerative and metabolic disease submarkets among others.

Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets.”

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Bristol-Myers Squibb, Pfizer, Bayer, Novartis, Roche, Sanofi & GSK.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever